Novartis is developing iloperidone under a licensing agreement with Titan Pharmaceuticals, while Renaissance Technologies bought a new stake in Black Titan Corp.
3 reports, 1 independent
Updated Aug 25
Gone quiet
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Novartis is developing iloperidone under a licensing agreement with Titan Pharmaceuticals, while Renaissance Technologies bought a new stake in Black Titan Corp.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Novartis
Swiss-American multinational pharmaceutical corporation
-
Titan Pharmaceuticals
California company with the stock symbol TTNP
Nothing else this week.
-
Renaissance Technologies
American hedge fund firm